

Appl. No. 10/535,000
Response to Office Action mailed September 3, 2008

R E M A R K S

The Examiner is respectfully requested to acknowledge applicants' claim for priority under 35 USC 119 and receipt of the certified copy of the priority document.

The Examiner is also respectfully requested to return copies of (i) the Forms PTO/SB/08A and PTO/SB/08B filed on May 16, 2005; (ii) the Form PTO/SB/08A filed on June 27, 2005; (iii) the IDS Forms filed on August 16, 2007 and (iv) the IDS Form filed on April 21, 2008, and to indicate thereon that all the cited publications were considered and made of record.

The Examiner is further respectfully requested to approve the drawing.

Restriction was required under 35 USC 121 as follows:

Group I. Claims 1 to 4, drawn to a composition comprising a Rho kinase inhibitor and a beta-blocker.

Group II. Claims 5 to 8, drawn to a method of treating glaucoma comprising administering a Rho kinase inhibitor and a beta-blocker.

Appl. No. 10/535,000
Response to Office Action mailed September 3, 2008

Group III. Claims 9 to 12, drawn to the use of a Rho kinase inhibitor and a beta-blocker.

Applicants elect Group I (claims 1 to 4, drawn to a composition comprising a Rho kinase inhibitor and a beta-blocker).

If the Examiner has any comments, questions, objections or recommendations, the Examiner is invited to telephone the undersigned at the telephone number given below for prompt action.

Frishauf, Holtz, Goodman
& Chick, P.C.
220 Fifth Ave., 16th Floor
New York, NY 10001-7708
Tel. Nos. (212) 319-4900
(212) 319-4551/Ext. 219
Fax No.: (212) 319-5101
E-Mail Address: BARTH@FHGC-LAW.COM
RSB/ddf

Respectfully submitted,



Richard S. Barth
Reg. No. 28,180